MUC1 and Familial prostate cancer: Similarly, Westdorp et al. found in a phase IIa clinical trial that vaccination using cDCs and pDCs in combination, loaded with the tumor-associated antigens NY-ESO-1, MAGE-C2, and MUC1, improved the clinical outcome of patients with castration-resistant prostate cancer (Westdorp, 2019).